Volume 112, Issue 3, July 2025, 116835Author links open overlay panelAlexandra Claudet a, Noémi Alcover a, Elise Lebigot b, Hana-Sofia Bouhelal a, Fairly Warnakulasuriya a, Marie-Pierre Soutiere a, Marie Galloux c, Jean-François Eleouet c, Marie-Anne Rameix-Welti d, Etienne Bizot e f, Christelle Vauloup-Fellous a f, Vincent Portet-Sulla a fShow moreHighlights•

Novel ELISA assays were developed for detecting anti-RSV and anti-influenza IgG.

•

The influenza vaccine-based ELISA achieved 98.3 % sensitivity and 100 % specificity.

•

The pre-fusion RSV F protein (Arexvy®) was the best antigen (97.5 % sensitivity, 97.4 % specificity).

•

Mixed antigen coatings (RSV F + N) performed worse than individual F protein assays.

AbstractIntroduction

Respiratory syncytial virus (RSV) and influenza are major causes of respiratory infections globally. Although vaccines are available, serological tools to assess population-level immunity and maternal antibody transfer remain limited. This study aimed to develop and evaluate ELISA assays for detecting anti-RSV and anti-influenza antibodies as a basis for future maternal-fetal immunity research.

Materials and Methods

In this study, we designed ELISA immunoassays using various influenza and RSV antigens. Sensitivity and specificity were calculated using sera from presumed seronegative infants and seropositive adults.

Results

The influenza vaccine-based ELISA achieved 98.3 % sensitivity and 100 % specificity. The pre-fusion F protein of RSV (Arexvy®) showed 97.5 % sensitivity and 97.4 % specificity. Other antigen combinations performed less optimally.

Discussion

These ELISA assays are scalable tools for seroepidemiological and maternal transfer studies. Future work will include correlation with neutralizing antibodies and paired maternal-infant analyses.

Previous article in issueNext article in issueKey words

RSV

Influenza

Serology

IgG

Transfer

Neonatal

Placental

Recommended articles

© 2025 The Author(s). Published by Elsevier Inc.